26 Oct 2020 Cingulate Therapeutics Presents Results of Pivotal Phase 2 Clinical Trial for Lead ADHD Candidate CTx-1301 at the American Association of Child and Adolescent Psychiatry Annual Meeting
Data Demonstrates Extended Duration, Fast Onset of Action, and the Potential for Elimination of Booster Doses KANSAS CITY, Kan., Oct. 26, 2020 /PRNewswire/ — Cingulate Therapeutics, a privately-held, clinical-stage, biopharmaceutical company focused on the development of innovative new products for